RPO LLC’s Amylyx Pharmaceuticals AMLX Stock Holding History

RPO LLC’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,136	Closed	-$45.9K	–	45
2024 Q4	$45.9K	Buy	+12,136	New	+$57.1K	0.04%	64

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

RPO LLC's AMLX Position: Q1 2025 in Review

RPO LLC sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2025, closing a stake of 12,136 shares — an estimated $45.9K sold.

RPO LLC first reported a position in AMLX in Q4 2024 and held it in 1 quarter. The position peaked at $45.9K in Q4 2024. 136 funds tracked by Wall St. Rank hold AMLX as of Q1 2025.

RPO LLC reported no remaining Amylyx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
RPO LLC sold 12,136 Amylyx Pharmaceuticals shares in Q1 2025, an estimated $45.9K.
RPO LLC first reported a position in Amylyx Pharmaceuticals in Q4 2024 and held it in 1 quarter.
RPO LLC's Amylyx Pharmaceuticals position peaked at $45.9K in Q4 2024.
136 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.